Skip to main content
SinoMab BioScience Limited logo

SinoMab BioScience Limited — Investor Relations & Filings

Ticker · 3681 ISIN · HK0000544194 LEI · 9845009B6CEEC4694006 HKEX Manufacturing
Open in API
Filings indexed 319 across all filing types
Latest filing 2026-03-10 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 3681

About SinoMab BioScience Limited

http://www.sinomab.com

SinoMab BioScience Limited is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of therapeutic antibodies. The company focuses on developing novel, highly efficacious drugs, including "first-in-class" and "best-in-class" candidates, primarily for the treatment of immunological and life-threatening diseases, such as rheumatoid arthritis. SinoMab maintains full-spectrum drug development capabilities, covering antibody re-engineering, bioprocessing, and manufacturing, aimed at addressing significant unmet medical needs globally.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1484 characters) from SinoMab BioScience Limited regarding the scheduling of a board meeting to approve upcoming financial results. It does not contain the financial results themselves, but rather notifies the market of the date for the board meeting to consider and publish them. According to the 'Menu vs Meal' rule, an announcement regarding the timing or publication of a report is classified as a Report Publication Announcement (RPA).
2026-03-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and public float. It does not represent a specific corporate event like an earnings release or a dividend announcement, but rather a recurring regulatory disclosure of share movements. Therefore, it falls under the 'Regulatory Filings' category.
2026-03-05 English
VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR IBD OF SM17 BY NMPA
Regulatory Filings Classification · 96% confidence The document is a voluntary announcement from SinoMab BioScience Limited regarding the approval of an Investigational New Drug (IND) application by the NMPA for their product SM17. It details the clinical significance, mechanism of action, and future development plans for the drug. As this is a regulatory announcement regarding company operations and product development that does not fit into specific financial reporting or governance categories, it is classified as a Regulatory Filing (RNS).
2026-02-24 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the Hong Kong Stock Exchange (HKEX) to report monthly movements in securities, share capital, and share options. It does not fit into specific categories like 'Share Issue' (as it reports no changes) or 'Transaction in Own Shares' (as it reports no buybacks), and it is a recurring regulatory disclosure rather than a one-off announcement. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in securities, including share capital, share options, and treasury shares. Since it is a recurring regulatory filing detailing changes in securities and capital structure, it falls under the 'Regulatory Filings' category as it does not represent a specific corporate event like a dividend announcement or a major shareholding notification.
2026-01-07 English
VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement issued by SinoMab BioScience Limited regarding the acceptance of an Investigational New Drug (IND) application by the NMPA CDE for their product SM17. It details the clinical development progress and the strategic rationale for expanding the product's indication. As this is a regulatory announcement regarding company operations and product development that does not fit into specific categories like financial reports, dividends, or director dealings, it is classified as a general regulatory filing.
2025-12-11 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.